The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Open accessAbstract
BACKGROUND: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab--which blocks cytotoxic T-lymphocyte-associated antigen 4 to potentiate an antitumor T-cell response--administered with or without a glycoprotein 100 (gp100) peptide vaccine was compared with gp100 alone in patients with previously treated metastatic melanoma. METHODS: A total of 676 HLA-A*0201-positive patients with unresectable stage III or IV melanoma, whose disease had progressed while they were receiving therapy for metastatic disease, were randomly assigned, in a 3:1:1 ratio, to receive ipilimumab plus gp100 (403 patients), ipilimumab alone (137), or gp100 alone (136). Ipilimumab, at a dose of 3 mg per kilogram of body weight, was administered with or without gp100 every 3 weeks for up to four treatments (induction). Eligible patients could receive reinduction therapy. The primary end point was overall survival. RESULTS: The median overall survival was 10.0 months among patients receiving ipilimumab plus gp100, as compared with 6.4 months among patients receiving gp100 alone (hazard ratio for death, 0.68; P<0.001). The median overall survival with ipilimumab alone was 10.1 months (hazard ratio for death in the comparison with gp100 alone, 0.66; P=0.003). No difference in overall survival was detected between the ipilimumab groups (hazard ratio with ipilimumab plus gp100, 1.04; P=0.76). Grade 3 or 4 immune-related adverse events occurred in 10 to 15% of patients treated with ipilimumab and in 3% treated with gp100 alone. There were 14 deaths related to the study drugs (2.1%), and 7 were associated with immune-related adverse events. CONCLUSIONS: Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Adverse events can be severe, long-lasting, or both, but most are reversible with appropriate treatment. (Funded by Medarex and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00094653.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In 2011, based on promising results from a clinical trial in melanoma patients, the first ICI therapy ipilimumab, an anti-CTLA-4 mAb, has gained FDA approval [98].”
From Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies (2025) · cites this paper as [98]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials of ICPis excluded patients with pre-existing active autoimmune diseases because of concerns of a high susceptibility to severe irAEs [49,50].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [49]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment with immunotherapy targeting checkpoint inhibitors PD-1 or CTLA-4 significantly increases survival in patients with metastatic melanoma over other standards of care [1, 2]”
From Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients (2019) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While immune checkpoint inhibitors (ICIs) have greatly enhanced clinical outcomes across multiple cancer types,1, 2, 3”
From irAE-GPT: leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“Antibodies against CTLA-4 (ipilimumab) or PD1 (nivolumab) have been shown to induce quick and intense tumor regression in melanoma and NSCLC patients and are currently under clinical investigation in other solid tumors, including CRC [132, 133]”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [132]
In the citing paper
“Even though ICIs have shown promising results in adults, there is limited data regarding their safety in children [145].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [145]
In the citing paper
“Ipilimumab (anti-CTLA4) was the first ICT to gain FDA approval in 2011 for the treatment of metastatic melanoma, on the basis of phase III trials demonstrating improvements in overall survival compared with vaccine or chemotherapy (37,38).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [37]
In the citing paper
“Ipilimumab was associated with long-term survival effects (1-year and 2-year survival rate of 45.6% and 23.5%, respectively).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Hodi et al., 2010
In the citing paper
“Treatment with Ipilimumab was associated with immune-related adverse events (irAEs) in a surprisingly high 60% of patients (Hodi et al., 2010);”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Hodi et al., 2010
In the citing paper
“Critically, analogous to what was observed in preclinical studies, the 20% of patients whose tumors were completely cleared maintained their response for the duration of the study, with a median follow-up time of approximately 30 months.”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [32]
In the citing paper
“The combination of ipilimumab and nivolumab has demonstrated enhanced response rates in melanoma, lung cancer, renal cell carcinoma, and mismatch repair deficient colon cancer compared with single agent therapy, although at a cost of increased toxicities (see next section).9–11”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [10]
In the citing paper
“In order to limit the risk of severe immune-related adverse events (irAEs) or exacerbation of underlying autoimmune or inflammatory disease, patients with preexisting autoimmune disorders (ADs) or those receiving systemic immunosuppression for organ transplantation have been universally excluded from clinical trials.3,4”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Self-citationCancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980
Melanoma biology and new targeted therapy
Gray-Schopfer, V., Wellbrock, C., & Marais, R. (2007) · Nature · doi:10.1038/nature05661 · Cited by 1,371
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Self-citationAttia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Self-citationManagement of Cutaneous Melanoma
Tsao, H., Atkins, M. B., & Sober, A. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041245 · Cited by 869
Korn, E. L., Liu, P.-Y., Lee, S. J., Chapman, J. W., Niedzwiecki, D., Suman, V. J., Moon, J., Sondak, V. K., Atkins, M. B., Eisenhauer, E. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7837 · Cited by 704
Immunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervás‐Stubbs, S., Glennie, M. J., Pardoll, D. M., & Chen, L. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2051 · Cited by 634
Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Lin R, 2008, J Clin Oncol, 26, 497s
Cited by
Sorted by citations
Items 701–800 of 1,189
Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence
Harel, M., Ortenberg, R., Varanasi, S. K., Mangalhara, K. C., Mardamshina, M., Markovits, E., Baruch, E. N., Tripple, V., Arama-Chayoth, M., Greenberg, E., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.012 · Cited by 328
Ravi, R., Noonan, K. A., Pham, V., Bedi, R., Zhavoronkov, A., Ozerov, I. V., Makarev, E., V. Artemov, A., Wysocki, P. T., Mehra, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02696-6 · Cited by 325
Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
Tang, C. Z., Wang, X., Soh, H., Seyedin, S. N., Cortez, M. A., Krishnan, S., Massarelli, E., Hong, D. S., Naing, A., Diab, A. K., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0069 · Cited by 325
Emerging Opportunities and Challenges in Cancer Immunotherapy
Whiteside, T. L., Demaria, S., Rodriguez-Ruiz, M. E., Zarour, H. M., & Melero, I. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0049 · Cited by 325
Cheng, K., Ding, Y., Zhao, Y., Ye, S., Zhao, X., Zhang, Y., Ji, T., Wu, H., Wang, B., Anderson, G. J., et al. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b01071 · Cited by 325
POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
van Gool, I. C., Eggink, F. A., Freeman-Mills, L., Stelloo, E., Marchi, E., de Bruyn, M., Palles, C., Nout, R. A., de Kroon, C. D., Osse, E. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0057 · Cited by 323
Schwarz, E. M., Parvizi, J., Gehrke, T. A., Aiyer, A. A., Battenberg, A. K., Brown, S., Callaghan, J. J., Çıtak, M., Egol, K. A., Garrigues, G. E., et al. (2019) · Journal of Orthopaedic Research® · doi:10.1002/jor.24293 · Cited by 323
Delphine Rossille, A., Gressier, M., Damotte, D., Maucort‐Boulch, D., Pangault, C., Sémana, G., Gouill, S. L., Haïoun, C., Tarte, K., Lamy, T., et al. (2014) · Leukemia · doi:10.1038/leu.2014.137 · Cited by 322
Nirschl, C. J., & Drake, C. G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1972 · Cited by 322
Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma
Keu, K. V., Witney, T. H., Yaghoubi, S. S., Rosenberg, J., Kurien, A., Magnusson, R., Williams, J. H. H., Habte, F. G., Wagner, J. R., Forman, S. J., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2196 · Cited by 322
Laubli, H. P., Balmelli, C., Bossard, M., Pfister, O., Glatz, K., & Zippelius, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0057-1 · Cited by 321
Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know
Rosenberg, S. A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.116 · Cited by 321
B7 family checkpoint regulators in immune regulation and disease
Ceeraz, S., Nowak, E. C., & Noelle, R. J. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.07.003 · Cited by 323
Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets
Müller, L., Mitsuhashi, M., Simms, P. E., Gooding, W. E., & Whiteside, T. L. (2016) · Scientific Reports · doi:10.1038/srep20254 · Cited by 321
Ipilimumab and Its Toxicities: A Multidisciplinary Approach
Fecher, L. A., Agarwala, S. S., Hodi, F. S., & Weber, J. S. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0483 · Cited by 320
Self-citationCD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
Dudley, M. E., Gross, C. A., Langhan, M. M., García, M. R., Sherry, R. M., Yang, J. C.-H., Phan, G. Q., Kammula, U. S., Hughes, M. S., Citrin, D. E., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1297 · Cited by 320
Harnessing the immune system to improve cancer therapy
Papaioannou, N. E., Beniata, O. V., Vitsos, P., Tsitsilonis, O., & Samara, P. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.04.01 · Cited by 320
Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
Fancello, L., Gandini, S., Pelicci, P. G., & Mazzarella, L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0647-4 · Cited by 325
3D bioprinting for reconstituting the cancer microenvironment
Datta, P., Dey, M., Ataie, Z., Unutmaz, D., & Ozbolat, I. T. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-0121-2 · Cited by 320
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
Holder, A. M., Dedeilia, A., Sierra-Davidson, K., Cohen, S., Liu, D., Parikh, A. R., & Boland, G. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00705-7 · Cited by 330
Delyon, J., Mateus, C., Lefeuvre, D., Lanoy, E., Zitvogel, L., Chaput, N., Roy, S., Eggermont, A. M. M., Routier, E., & Robert, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt027 · Cited by 318
Self-citationImmunomodulatory effects of cyclophosphamide and implementations for vaccine design
Sistigu, A., Viaud, S., Chaput, N., Bracci, L., Proietti, E., & Zitvogel, L. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0245-0 · Cited by 318
Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment
Hadrup, S. R., Donia, M., & Straten, P. T. (2012) · Cancer Microenvironment · doi:10.1007/s12307-012-0127-6 · Cited by 318
Targeting Cancer-Derived Adenosine:New Therapeutic Approaches
Young, A., Mittal, D., Stagg, J., & Smyth, M. J. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0341 · Cited by 318
Tison, A., Quéré, G., Misery, L., Funck‐Brentano, E., Danlos, F., Routier, É., Robert, C., Loriot, Y., Lambotte, O., Bonniaud, B., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41068 · Cited by 317
Self-citationIL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy
Weber, R., Groth, C., Lasser, S., Arkhypov, I., Petrova, V., Altevogt, P., Utikal, J. S., & Umansky, V. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104254 · Cited by 317
Self-citationCTLA-4 in Regulatory T Cells for Cancer Immunotherapy
Sobhani, N., Tardiel-Cyril, D. R., Davtyan, A., Generali, D., Roudi, R., & Li, Y. (2021) · Cancers · doi:10.3390/cancers13061440 · Cited by 317
Sharma, A., Subudhi, S. K., Blando, J. M., Vence, L. M., Wargo, J. A., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0402 · Cited by 317
Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
Eroglu, Z., & Ribas, A. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015616934 · Cited by 316
Tarhini, A. A., Edington, H. D. J., Butterfield, L. H., Lin, Y., Shuai, Y., Tawbi, H. A., Sander, C., Yin, Y., Holtzman, M. P., Johnson, J. T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087705 · Cited by 316
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
Tanaka, S., Louis, D. N., Curry, W. T., Batchelor, T. T., & Dietrich, J. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.204 · Cited by 317
Wilgenhof, S., Corthals, J., Heirman, C., van Baren, N., Lucas, S., Kvistborg, P., Thielemans, K., & Neyns, B. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4121 · Cited by 316
Kohlhapp, F. J., & Kaufman, H. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2667 · Cited by 315
Time to abandon single-site irradiation for inducing abscopal effects
Brooks, E. D., & Chang, J. Y. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0119-7 · Cited by 315
Beatty, G. L., O'Dwyer, P. J., Clark, J., Shi, J. G., Bowman, K. J., Scherle, P. A., Newton, R. C., Schaub, R., Maleski, J., Leopold, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2272 · Cited by 314
Self-citationB Cells Regulate Macrophage Phenotype and Response to Chemotherapy in Squamous Carcinomas
Affara, N. I., Ruffell, B., Medler, T. R., Gunderson, A. J., Johansson, M., Bornstein, S., Bergsland, E. K., Steinhoff, M. S., Li, Y., Gong, Q., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.026 · Cited by 314
Joseph, R. W., Elassaiss‐Schaap, J., Kefford, R. F., Hwu, W., Wolchok, J. D., Joshua, A. M., Ribas, A., Hodi, F. S., Hamid, O., Robert, C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2386 · Cited by 314
Self-citationCombining Epigenetic and Immunotherapy to Combat Cancer
Chiappinelli, K. B., Zahnow, C. A., Ahuja, N., & Baylin, S. B. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2125 · Cited by 313
Cancer and the Immune System: Basic Concepts and Targets for Intervention
Pardoll, D. M. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.003 · Cited by 312
Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages
Yan, W., Liu, X., Ma, H., Zhang, H., Song, X., Gao, L., Liang, X., & Ma, C. (2015) · Gut · doi:10.1136/gutjnl-2014-307671 · Cited by 311
Delivering safer immunotherapies for cancer
Milling, L. E., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 311
Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy
Galstyan, A., Markman, J. L., Shatalova, E. S., Chiechi, A., Korman, A. J., Patil, R., Klymyshyn, D., Tourtellotte, W. G., Israel, L. L., Braubach, O., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11719-3 · Cited by 311
Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression
Pu, Y., & Ji, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.874589 · Cited by 311
T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants
Hirschhorn, D., Budhu, S., Kraehenbuehl, L., Gigoux, M., Schröder, D., Chow, A. T., Ricca, J. M., Gasmi, B., Henau, O. D., Mangarin, L. M. B., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.007 · Cited by 311
Self-citationTemozolomide for immunomodulation in the treatment of glioblastoma
Karachi, A., Dastmalchi, F., Mitchell, D. A., & Rahman, M. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy072 · Cited by 310
Stromal Cells in the Tumor Microenvironment
Denton, A. E., Roberts, E. W., & Fearon, D. T. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-78127-3_6 · Cited by 311
Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
Ciardiello, D., Vitiello, P. P., Cardone, C., Martini, G., Troiani, T., Martinelli, E., & Ciardiello, F. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.04.003 · Cited by 310
Qing, S., Lyu, C., Zhu, L., Pan, C., Wang, S., Li, F., Wang, J., Yue, H., Gao, X., Jia, R., et al. (2020) · Advanced Materials · doi:10.1002/adma.202002085 · Cited by 309
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
Wolchok, J. D., Hodi, F. S., Weber, J. S., Allison, J. P., Urba, W. J., Robert, C., O'Day, S. J., Hoos, A., Humphrey, R. W., Berman, D. M., et al. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12180 · Cited by 309
Self-citationCurrent and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review
Daher, S., Massarwa, M., Benson, A. A., & Khoury, T. (2017) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00031 · Cited by 309
Choi, J., & Lee, S. Y. (2020) · Immune Network · doi:10.4110/in.2020.20.e9 · Cited by 309
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
Garbe, C., Amaral, T. M. S., Peris, K., Hauschild, A., Arenberger, P., Basset‐Séguin, N., Bastholt, L., Bataille, V. A., del Mármol, V., Dréno, B., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.04.018 · Cited by 309
Self-citationDiem, S., Kasenda, B., Spain, L., Martin-Liberal, J., Marconcini, R., Gore, M., & Larkin, J. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.467 · Cited by 308
T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?
Speiser, D. E., Utzschneider, D. T., Oberle, S. G., Münz, C., Romero, P. J., & Zehn, D. (2014) · Nature reviews. Immunology · doi:10.1038/nri3740 · Cited by 308
Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia
Rajasagi, M., Shukla, S. A., Fritsch, E. F., Keskin, D. B., DeLuca, D. S., Carmona, E. M., Zhang, W., Sougnez, C. L., Cibulskis, K., Sidney, J., et al. (2014) · Blood · doi:10.1182/blood-2014-04-567933 · Cited by 308
Thomas, A., Rajan, A., Berman, A. W., Tomita, Y., Brzezniak, C. E., Lee, M.-J., Lee, S., Ling, A. L., Spittler, A. J., Carter, C. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71181-7 · Cited by 308
Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2—Tumor and Immunological Responses
Seung, S. K., Curti, B. D., Crittenden, M. R., Walker, E., Coffey, T. S., Siebert, J., Miller, W. L., Payne, R., Glenn, L. A., Bageac, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003649 · Cited by 307
Self-citationTim-3: An Emerging Target in the Cancer Immunotherapy Landscape
Anderson, A. C. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0039 · Cited by 307
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
Kelderman, S., Heemskerk, B., van Tinteren, H., van den Brom, R. R. H., Hospers, G. A. P., van den Eertwegh, A. J. M., Kapiteijn, E., de Groot, J. W. B., Soetekouw, P. M. M. B., Jansen, R. L. H., et al. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1528-9 · Cited by 307
Self-citationAli, H. R., Glont, S.-E., Blows, F. M., Provenzano, E., Dawson, S., Liu, B., Hiller, L., Dunn, J., Poole, C. J., Bowden, S. J., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv192 · Cited by 306
Kong, Y., Zhu, L., Schell, T. D., Zhang, J., Claxton, D. F., Ehmann, W. C., Rybka, W. B., George, M. R., Zeng, H., & Zheng, H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2626 · Cited by 306
Yue, E. W., Sparks, R. B., Polam, P. K., Modi, D., Douty, B. D., Wayland, B. R., Glass, B. M., Takvorian, A. G., Glenn, J., Zhu, W., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00391 · Cited by 306
Phuengkham, H., Ren, L. F., Shin, I. W., & Lim, Y. T. (2019) · Advanced Materials · doi:10.1002/adma.201803322 · Cited by 306
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies
Sullivan, R. J., & Weber, J. S. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00259-5 · Cited by 312
Self-citationTransient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy
Bos, P. D., Plitas, G., Rudra, D., Lee, S. Y., & Rudensky, A. Y. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20130762 · Cited by 305
Seethapathy, H. S., Zhao, S. J., Chute, D. F., Zubiri, L., Oppong, Y. D., Strohbehn, I. A., Cortazar, F. B., Leaf, D. E., Mooradian, M. J., Villani, A., et al. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00990119 · Cited by 305
The immune system and cancer evasion strategies: therapeutic concepts
Muenst, S., Läubli, H., Soysal, S. D., Zippelius, A., Tzankov, A., & Hoeller, S. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12470 · Cited by 304
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H. E. K., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J. A., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci73340 · Cited by 304
Kostine, M., Finckh, A., Bingham, C. O., Visser, K., Leipe, J., Schulze‐Koops, H., Choy, E., Benesova, K., Radstake, T. R. D. J., Cope, A. P., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217139 · Cited by 307
Self-citationAn early history of T cell-mediated cytotoxicity
Golstein, P., & Griffiths, G. M. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0009-3 · Cited by 303
Immune Checkpoint Inhibitor-Associated Myocarditis
Ganatra, S., & Neilan, T. G. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0130 · Cited by 303
A review of glioblastoma immunotherapy
Medikonda, R. T., Dunn, G. P., Rahman, M., Fecci, P. E., & Lim, M. K. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03448-1 · Cited by 307
B7-H3/CD276: An Emerging Cancer Immunotherapy
Zhou, W.-T., & Jin, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.701006 · Cited by 303
Regulatory T cells in the treatment of disease
Sharabi, A., Tsokos, M., Ding, Y., Malek, T. R., Klatzmann, D., & Tsokos, G. C. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.148 · Cited by 301
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
Fan, X., Quezada, S. A., Sepulveda, M. A., Sharma, P., & Allison, J. P. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20130590 · Cited by 300
Spranger, S. (2016) · International Immunology · doi:10.1093/intimm/dxw014 · Cited by 300
Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay
Pastor, F., Kolonias, D. S., Giangrande, P. H., & Gilboa, E. (2010) · Nature · doi:10.1038/nature08999 · Cited by 299
Safety of combining radiotherapy with immune-checkpoint inhibition
Hwang, W. L., Pike, L., Royce, T. J., Mahal, B. A. V., & Loeffler, J. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0046-7 · Cited by 299
Chandran, S. S., Somerville, R. P. T., Yang, J. C.-H., Sherry, R. M., Klebanoff, C. A., Goff, S. L., Wunderlich, J. R., Danforth, D. N., Zlott, D. A., Paria, B. C., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30251-6 · Cited by 297
Combined immune checkpoint blockade as a therapeutic strategy for BRCA1 -mutated breast cancer
Nolan, E., Savas, P. S., Policheni, A. N., Darcy, P. K., Vaillant, F., Mintoff, C., Dushyanthen, S., Mansour, M., Pang, J., Fox, S. B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal4922 · Cited by 297
Cancer immune evasion, immunoediting and intratumour heterogeneity
Roerden, M., & Spranger, S. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-024-01111-8 · Cited by 297
Immunotherapy, Inflammation and Colorectal Cancer
Lichtenstern, C. R., Ngu, R. K., Shalapour, S., & Karin, M. (2020) · Cells · doi:10.3390/cells9030618 · Cited by 296
Abdel-Wahab, N., Safa, H., Abudayyeh, A., Johnson, D. H., Trinh, V. A., Zobniw, C. M., Lin, H., Wong, M. K., Abdelrahim, M., Gaber, A. O., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0585-1 · Cited by 294
CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy
Engeland, C. E., Grossardt, C., Veinalde, R., Bossow, S., Lutz, D., Kaufmann, J. K., Shevchenko, I., Umansky, V., Nettelbeck, D. M., Weichert, W., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.160 · Cited by 294
Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017
Ugurel, S., Röhmel, J., Ascierto, P. A., Flaherty, K. T., Grob, J., Hauschild, A., Larkin, J., Long, G. V., Lorigan, P. C., McArthur, G. A., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.028 · Cited by 294
Self-citationSznol, M., Ferrucci, P. F., Hogg, D., Atkins, M. B., Wolter, P., Guidoboni, M., Lebbé, C., Kirkwood, J. M., Schachter, J., Daniels, G. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1167 · Cited by 294
Self-citationWallis, C. J. D., Butaney, M., Satkunasivam, R., Freedland, S. J., Patel, S. P., Hamid, O., Pal, S. K., & Klaassen, Z. W. A. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5904 · Cited by 294
Interferon-γ links ultraviolet radiation to melanomagenesis in mice
Zaidi, M. R., Davis, S., Noonan, F. P., Graff-Cherry, C., Hawley, T. S., Walker, R. L., Feigenbaum, L., Fuchs, E., Lyakh, L., Young, H. A., et al. (2011) · Nature · doi:10.1038/nature09666 · Cited by 293
Translational value of mouse models in oncology drug development
Gould, S. E., Junttila, M. R., & de Sauvage, F. J. (2015) · Nature Medicine · doi:10.1038/nm.3853 · Cited by 293
Nishijima, T. F., Muss, H. B., Shachar, S. S., & Moschos, S. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.006 · Cited by 293
Kohrt, H. E. K., Thielens, A., Marabelle, A., Sagiv-Barfi, I., Sola, C., Chanuc, F., Fuséri, N., Bonnafous, C., Czerwinski, D. K., Rajapaksa, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-519199 · Cited by 293
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Lee, J., Lee, H. T., Shin, W., Chae, J., Choi, J., Kim, S. H., Lim, H., Heo, T. W., Park, K. Y., Lee, Y. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms13354 · Cited by 293
Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
Saleh, R., & Elkord, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.017 · Cited by 292
Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge
Makkouk, A., & Weiner, G. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2538 · Cited by 293
Castillo, M. D., Romero, F. A. R., Argüello, E., Kyi, C., Postow, M. A., & Redelman‐Sidi, G. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw539 · Cited by 292
Pembrolizumab for the treatment of non-small cell lung cancer
Lim, S. H., Sun, J., Lee, S., Ahn, J. S., Park, K., & Ahn, M. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1145652 · Cited by 292
Radiation and immunotherapy: a synergistic combination
Kalbasi, A. K., June, C. H., Haas, N. B., & Vapiwala, N. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69219 · Cited by 291
Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
Ting, N. L.-N., Lau, H. C.-H., & Yu, J. Q. (2022) · Gut · doi:10.1136/gutjnl-2021-326264 · Cited by 297
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
Quezada, S. A., Peggs, K. S., Simpson, T. R., & Allison, J. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01007.x · Cited by 290
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1
Naidoo, J., Schindler, K., Querfeld, C., BUSAM, K. J., Cunningham, J. D., Page, D. B., Postow, M. A., Weinstein, A., Lucas, A. S., Ciccolini, K. T., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0123 · Cited by 290
Self-citation
Metadata
- Authors
- Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J. M., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbé, C., Peschel, C., Quirt, I., Clark, J. I., Wolchok, J. D., Weber, J. S., Tian, J., Yellin, M. J., Nichol, G. M., Hoos, A., & Urba, W. J.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Angeles Clinic and Research Institute (US)
- Beth Israel Deaconess Medical Center (US)
- St. Mary's Medical Center (US)
- Vanderbilt University Medical Center (US)
- The Netherlands Cancer Institute (NL)
- University of Colorado Cancer Center (US)
- Institut Gustave Roussy (FR)
- Essen University Hospital (DE)
- University of Mannheim (DE)
- Huntsman Cancer Institute (US)
- Mount Sinai Medical Center (US)
- The Christie Hospital (GB)
- Washington University in St. Louis (US)
- Princess Margaret Cancer Centre (CA)
- University Hospital Southampton NHS Foundation Trust (GB)
- Technical University of Munich (DE)
- Loyola University Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- Moffitt Cancer Center (US)
- Bristol-Myers Squibb (United States) (US)
- ORCID
- Hodi, F. Stephen
- O'Day, Steven J.
- McDermott, David F.
- Sosman, Jeffrey A.
- Haanen, John B.
- Gonzalez, Rene
- Robert, Caroline
- Schadendorf, Dirk
- Hassel, Jessica C.
- Akerley, Wallace
- Lutzky, Jose
- Lorigan, Paul
- Linette, Gerald P.
- Hogg, David
- Ottensmeier, Christian H.
- Peschel, Christian
- Clark, Joseph I.
- Wolchok, Jedd D.
- Weber, Jeffrey S.
- Yellin, Michael J.
- Hoos, Axel
- Urba, Walter J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-08-19
- Volume
- 363
- Issue
- 8
- Pages
- 711-723
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3549297
- OpenAlex
- W2097995306
- Semantic Scholar
- 51d02526aa36effc4d0eedb5649b37a0fbfc57eb
- Cited by
- 15,155
- References
- 37
- Citations by year
- 2026: 414 · 2025: 584 · 2024: 743 · 2023: 876 · 2022: 880 · 2021: 1154 · 2020: 1165 · 2019: 1106 · 2018: 1215 · 2017: 1290 · 2016: 1262 · 2015: 1265 · 2014: 1017 · 2013: 898 · 2012: 692
- FWCI
- 341.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Syracuse University
- Moffitt Cancer Center
- National Cancer Institute (K24CA097588)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- ipilimumab, metastatic melanoma, CTLA-4 blockade, immune checkpoint inhibitors, overall survival, immune-related adverse events, HLA-A*0201, cancer immunotherapy, reinduction therapy, T cell response, immune-related pneumonitis, immune-related colitis
- MeSH terms
- Ipilimumab, Antibodies, Monoclonal, Combined Modality Therapy, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Antigens, CD, Treatment Outcome, Cancer Vaccines, Kaplan-Meier Estimate, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
